An interventional study of extra blood sampling in NASH and NAFLD, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy — 21 open to participants now, 29 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Italy.
Among the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy, this one is the 15th largest by planned enrollment of the 75 interventional ones that give a count, is one of 10 that started in 2024, is one of 31 with no phase, reaches primary completion later than 12 of the 28 other live ones, and was the 93rd registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →21 of the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy are open now. Recruiting first, the newest first:
University of Palermo · Sites in Italy
Ages 1–14
Eli Lilly and Company · Sites in Italy, United States, Argentina and 31 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Akero Therapeutics, Inc · Sites in Italy, United States, Argentina and 20 more countries
Ages 18–80
The Cleveland Clinic · Sites in Italy, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 24 · Phase 3 19 · Phase 4 2
First in 2003; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 408 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 150 across the 75 interventional studies, 136 across the 24 observational. Of the 55 that completed or were terminated, 25 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 99 have an industry lead sponsor. The 10 most frequent:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 6 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Non-alcoholic Fatty Liver Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06537466University of PalermoKetogenic Diet in MASLD-related cACLD | 2026-11 |
| NCT06888310Fondazione Policlinico Universitario Agostino Gemelli IRCCSOptimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease | 2026-12-01 |
| NCT06879236Fondazione Policlinico Universitario Agostino Gemelli IRCCSSecondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease | 2026-12-14 |
| NCT07644936Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisMolecular Characterization of Autoimmune Hepatitis: A Lipidomic Approach | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 99 studies in Non-alcoholic Fatty Liver Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Non-alcoholic fatty liver disease (NAFLD) is responsible for a significant proportion of liver-related deaths and healthcare costs in the United States, accounting for approximately 36% of liver-related deaths and over one billion dollars in annual healthcare expenses. [PMID: 34863359] A recent analysis of healthcare costs in Italy showed that out of the 9,729 NAFLD/NASH patients who were hospitalized and analyzed, the vast majority (97%) did not have advanced liver disease, while 1.3% had compensated advanced liver disease (cACLD), 3.1% had decompensated cirrhosis, 0.8% had hepatocellular carcinoma, and 0.1% underwent liver transplantation.
The burden of comorbidities was high across all patient cohorts, and patients with cACLD required a greater number of inpatient services, outpatient visits, and the pharmacy fills compared to those without advanced liver disease. As disease severity increased, mean total annual costs also increased primarily due to higher inpatient services costs. In Italy, as in other EU countries, most of the healthcare costs for patients were attributed to NAFLD/NASH-related liver complications. Thus, the optimization of the non-invasive diagnosis of cACLD represents an urgent need in dysmetabolic liver disease. These advancements will play a crucial role in early detection, risk stratification, and effective management of highly prevalent liver diseases such as NAFLD/NASH and their progression.
The study aims to significantly enhance diagnostic innovation and contribute to the existing literature on the stratification of cACLD caused by metabolic-dysfunction liver disease, a major factor leading to cirrhosis, liver cancer, and liver transplant in individuals with non-communicable diseases. By integrating radiomics, digital pathology, non-invasive scores, and omics the results are expected to provide novel evidence for diagnostic advancements.
The incorporation of AI is anticipated to lead to more efficient diagnostic management, effectively addressing the impact of cACLD on healthcare systems. The outcomes of this research will yield a substantial database and intellectual content, both of which will be made available to the scientific community and multiple stakeholders, including patient associations, policymakers, healthcare providers, and industry players.
The primary goal is to foster innovation in diagnostics and mitigate the impact of cACLD on national health systems. By accurately predicting individuals at higher risk of liver or extra-hepatic complications, this study aims to revolutionize diagnostic methods, ultimately leading to improved patient outcomes and resource optimization in healthcare settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To set an interventional prospective, cohort study where individuals will have a liver health check to identify cACLD. We will exclude subjects with decompensation (ascites, encephalopathy, gastrointestinal bleeding, or in case of the presence of transjugular intrahepatic portosystemic shunt). We aim to recruit a prospective cohort and randomize after the end of the study to derivation (2/3) and validation cohort (1/3). The cohort will be stratified according to the presence of Type 2 diabetes (T2D) and obesity (BMI\>= 30Kg/m2).
Procedure: extra blood sampling
search for biomarkers for the prevention of liver disease
number of patients identified with single diagnostic method
evaluate the efficacy of risk-stratification pathways for cACLD detection and outcome prediction in adults (age\>18 years) with dysmetabolic liver disease in a tertiary care setting.
Time frame: 24 months
number of patients identified with innovative diagnostic method omic-based
evaluate the possible integration of liquid biopsy for cACLD detection and outcome prediction
Time frame: 24 months
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 23 months is below that.
Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →